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A twelve-year-old girl presented with a history of several weeks of worsening headaches accompanied by flushing and diaphoresis.
The discovery of markedly elevated blood pressure and tachycardia led the child’s pediatrician to consider the diagnosis of a
catecholamine-secreting tumor, and an abdominal CT scan confirmed the presence of a pheochromocytoma. The patient was found
to have a mutation in the succinyl dehydrogenase B (SDHB) gene, which is causative for SDHB-related hereditary paragangliomapheochromocytoma syndrome. Herein, we describe her presentation and medical management and discuss the clinical implications
of SDHB deficiency.

1. Case Presentation
A previously healthy 12-year-old girl presented with worsening headaches of six-month duration, described as diffuse,
throbbing, and intense, occurring daily and lasting up to
eight hours or more. They were not associated with time
of day, posture, activity, and prodromal visual, auditory, or
gustatory symptoms, and there were no associated neurologic
abnormalities. Headaches were occasionally accompanied by
lightheadedness, nausea, palpitations, and flushing. She had
lost roughly 25% of her preillness body weight, had been
fatigued and “warm,” and noted polydipsia and polyuria
for several days prior to admission. The patient’s mother,
an experienced cardiology nurse, reported that the patient’s
blood pressure had been as high as 200/160 mmHg. The
patient had a history of prematurity, being born at 27-week
gestation and requiring intubation and mechanical ventilation for prematurity-induced respiratory distress. However,

aside from exercise-induced reactive airways disease, she
had no other ongoing medical problems. The patient had
normal growth and development and was doing well in
school. Family history was noncontributory for oncologic or
endocrine diseases.
At her primary care physician’s office, the patient’s blood
pressure was 205/160 mmHg, and the heart rate was 120 beats
per minute. An abdominal CT scan, ordered to investigate
the possibility of a neuroendocrine tumor, revealed a large
right-sided suprarenal mass, which prompted a referral to our
institution for further workup and management. The patient
was referred to our service with the presumptive diagnosis
of malignant hypertension secondary to a catecholaminesecreting pheochromocytoma (PCC) of the right adrenal
gland. On arrival, the patient was alert, well-appearing, and
in no distress. She was well-developed and nondysmorphic.
The height was 152 cm (25th percentile for age) and weight
was 54 kg (75th percentile for age). She was afebrile, the

2

Case Reports in Genetics
Table 1: Presenting serum and urine catecholamine levels.

Test
Plasma
(i) Total catecholamines
(ii) Norepinephrine
(iii) Dopamine
(iv) Epinephrine
Urine
(i) Total metanephrines
(ii) Normetanephrine
(iii) Homovanillic acid
(iv) Metanephrine

Patient result

Normal range

>8,705 pg/mL
>8,000 pg/mL
653 pg/mL
52 pg/mL

123–1,125 pg/mL
112–1,109 pg/mL
10–20 pg/mL
50–95 pg/mL

9,907 mcg
9,828 mcg
66.1 mg
79 mcg

110–714 mcg
67–503 mcg
<6.8 mg
<275 mcg

respiratory rate was 20 breaths per minute, the heart rate
was 124 beats per minute and regular, and the blood pressure
was 157/107 mmHg (the 95th percentile for a girl her age and
height is 123/80 mmHg). Oxygen saturation was >95% on
room air. She was mildly diaphoretic but had normal skin
turgor and perfusion. Capillary refill was brisk and she was
slightly flushed in her cheeks. Skin examination revealed no
rashes, abnormal lesions, growths, café-au-lait spots, or axillary freckling. Cardiac examination revealed a hyperdynamic
precordium and a grade II/VI systolic murmur best heard
at the upper left sternal border. Peripheral pulses were 2+
throughout and all extremities were warm and well-perfused.
The abdomen was soft, nontender, and nondistended without
palpable masses or organomegaly. The patient was alert and
oriented to person, place, and time. The neurologic and
musculoskeletal exams were nonfocal.
The patient’s CBC, differential, peripheral blood smear,
electrolytes, and liver function tests were all normal except
for serum glucose of 125 mg/dL (normal 60–99 mg/dL).
Serum uric acid was mildly elevated at 7.0 mg/dL (2.3–
5.9 mg/dL), and serum lactate dehydrogenase (LDH) fell
within the normal range (201 U/L; normal 110–293 U/L).
Ionized calcium, serum cortisol, and thyroid stimulating hormone (TSH) were normal. Serum and urine catecholamines
were markedly abnormal, especially plasma norepinephrine
and urine normetanephrine (Table 1). Radiographic imaging
confirmed a large right-sided suprarenal mass (Figure 1).
The patient was diagnosed with malignant hypertension secondary to PCC. She was placed on telemetry and was started
on intravenous fluids and 𝛼-blockade with phenoxybenzamine; headaches, flushing, diaphoresis, and nausea resolved
within 24 hours. The patient was treated with progressive 𝛼
and 𝛽 catecholamine blockade (Table 2); the patient’s medication history and vital findings are summarized (Figure 2).
The tumor was completely resected on the fifteenth day
of catecholamine blockade. The patient tolerated anesthesia
well, and the blood pressure and heart rate remained stable. The patient’s postoperative course was complicated by
rebound hypotension requiring robust fluid support which
led to pulmonary edema and respiratory failure requiring
mechanical ventilation and pressor support. The patient
recovered and was discharged 10 days after tumor resection.
Histologic examination of the resected tumor confirmed that
it was a PCC (Figure 3).

Currently, the patient is well now nine months after diagnosis. She is symptom-free and has normal blood pressure
and plasma catecholamines. Because of the strong association
between PCC and inherited cancer syndromes, the patient
was evaluated for known genetic mutations associated with
PCC and PGL (paraganglioma). The NF1, RET, TMEM127,
VHL, MAX, and succinate dehydrogenase (SDHx) genes
were sequenced, revealing a p.R27∗ point mutation in SDHB
(c.79C>T) resulting in the change of a cytosine to a thymine
and creating a premature stop codon in exon 2. This mutation,
known to predispose to PGLs and PCCs, also increases risk
for renal cell carcinoma [1–8].
Because of the risk of relapse and/or development of
a secondary malignancy, we have educated the patient
and her family about signs/symptoms that might indicate
disease recurrence (e.g., headache, hypertension, flushing,
diaphoresis, etc.). Following National Comprehensive Cancer
Network (NCCN) guidelines, our surveillance plan includes
a careful history and physical, blood pressure measurement,
and urine and plasma catecholamine assessment every three
months through the first year and every 6–12 months
thereafter through 10 years. We will incorporate abdominal
ultrasonography and/or MRI at her clinic visits as well
as yearly FDG-PET scans. Critically, we have referred her
immediate family for formal genetic evaluation to screen
for SDHB mutations and to provide genetic counseling
regarding the implications of the patient’s identified cancer
syndrome.

2. Discussion
PCCs and PGLs are neuroendocrine tumors that arise from
chromaffin cells in the adrenal gland (PCC) or in extraadrenal sympathetic nerve ganglia (PGL). Because of their
chromaffin cell origin, PCCs secrete catecholamines, which
explains the underlying sympathetic paraneoplastic symptoms many patients exhibit. However, unlike normal chromaffin cells which are innervated by sympathetic neurons and
release catecholamines only when initiated by an appropriate
neural impulses, PCCs produce and release catecholamines
in an unregulated and markedly exaggerated way. As with our
patient, PCCs frequently come to medical attention because
of symptoms of catecholamine excess rather than because
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Figure 1: Radiologic imaging of the patient at presentation. (a, b, c) Computed tomography images showing a right-sided contrast-enhancing
suprarenal mass (white arrows) displacing both the kidney and the liver. Note calcifications in the mass (arrow; image (c)), which is typical
for pheochromocytoma. (d) MIBG nuclear scan showing uptake by the adrenal mass (arrow) and no evidence of other sites of disease.
Table 2: Suggested algorithm for preoperative catecholamine blockade for PCC/PGL. Patients are best managed first with a pure alpha
adrenergic blockade to relax arteriolar smooth muscles and reduce catecholamine-induced blood vessel constriction. Once the blood pressure
is well-controlled, beta blockers can be added to treat tachycardia.
Medication

Recommended dose

(i) Days 1-2: 0.2 mg/kg (max 10 mg) q12h
(ii) Days 3-4: 0.2 mg/kg q8h
(iii) Days 5-6: 0.2 mg/kg q6h
Phenoxybenzamine (iv) Days 7-8: 0.4 mg/kg (max 20 mg) q6h
(v) Days 9-10: 0.4 mg/kg qid
(vi) Days 11-12: 0.6 mg/kg (max 30 mg/dose) q6h
(vii) Days 13-14: 0.6–0.8 mg/kg q6h
Beta blockade

Propranolol 0.5 mg/kg/dose tid and advanced as
necessary to keep HR <110

Notes
(i) Goal is low normal blood pressure, at least below 50th
percentile but preferably below 25th percentile
(ii) Side effects: congestion, tachycardia, hypotension,
dizziness, especially when standing up (and true orthostatic
hypotension), malaise, anorexia, and very rare allergic
reactions
(iii) Simultaneously load the patient with salt and water to
allow maximum blockade
(i) Should never be used as a first agent
(ii) Helpful for symptomatic tachycardia
(iii) Begin 5–7 days after phenoxybenzamine

Notes that if the timetable for surgery must be compressed (so that surgical resection is planned 7-8 days after diagnosis), we consider advancing catecholamine
blockade daily and using metyrosine to reduce amount of catecholamines produced by the tumor.

of problems caused by the tumor itself. Most PCCs, including those presenting in childhood, preferentially secrete
norepinephrine but they can also secrete epinephrine and
dopamine. Catecholamines mediate their effects through 𝛼adrenergic and 𝛽-adrenergic receptors. Alpha effects include
arteriolar constriction causing hypertension and diminished insulin secretion and enhanced gluconeogenesis and
glycogenolysis all of which promote hyperglycemia. Beta
stimulation, on the other hand, enhances cardiac contractility

and rate. The most common presenting signs and symptoms, therefore, include tachycardia, hypertension, palpitations, diaphoresis, flushing, and headache. Weight loss is
common because of a chronic hypermetabolic state. Early
identification is critical to prevent secondary complications
including myocardial infarction, cerebrovascular accident,
renal injury, and arterial aneurysms. Other conditions to
consider in the differential diagnosis include neuroblastoma,
coarctation of the aorta, and other causes of hypertension.
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Figure 2: Sympathetic blockade and vital signs. Clinical data showing heart rate, systolic blood pressure, and diastolic blood pressure from
admission until the time of tumor resection. Also shown are anticatecholamine medications and their doses over time. Note the progressive
decreases in hypertension and tachycardia over the patient’s hospital course.
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Figure 3: Pathologic images of resected tumor. (a, b) H & E-stained sections of the tumor showing tumor cells with abundant eosinophilic
cytoplasm arranged in a nested and trabecular pattern and surrounded by fibrovascular stroma. (c) Chromogranin A staining demonstrating
strong positivity of tumor cells. (d) Ki67 (MIB-1) immunostaining confirmed a high proliferation index (>10%) of the tumor cell population.
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Diagnosis of PCCs relies on detection of elevations of
catecholamines and metanephrines in plasma and/or the
urine. Plasma metanephrine testing is preferred to urine
testing. Radiologic imaging localizes and confirms tumor
presence. Beside conventional imaging modalities such as
computed tomography (CT) or magnetic resonance imaging
(MRI), nuclear medicine approaches such as FDG-PET
scanning can be helpful in tumor localization and staging.
DOPA-PET scanning is highly specific to catecholamineproducing tumors and therefore can be useful in differentiating PCC/PGL from other metabolically active lesions such as
inflammatory or infectious lymph nodes [9, 10]. Alternatively,
because cells in sympathetic neurons preferentially take up
metaiodobenzylguanidine, MIBG scanning is used in certain
centers to determine anatomic sites of PCC involvement.
The annual incidence rate for PCCs and PGLs is roughly
1 in 100,000 persons, with up to 20% occurring in the
pediatric age range. Among affected children, 70% of cases
are unilateral, are localized to the adrenal gland, and are
presenting between the ages of 6 and 14 years with a mean
of 11 years. The majority of PCCs diagnosed in children
are benign, with tumors remaining localized to their site of
origin and cured by surgical resection alone [11]. Because
of unregulated sympathetic release, PCCs can precipitate
serious comorbid conditions; therefore, timely diagnosis and
management are important [12]. Caution must be taken in
preparing patients with PCCs for tumor resection because of
the risk of dramatic blood pressure swings. Catecholamine
blockade before surgery is critical to avoid unpredictable
and exaggerated catecholamine release at the time of tumor
resection [13]. Perioperative mortality has dropped from as
high as 40% to under 3% over the last several decades because
of more effective preoperative catecholamine blockade, better
diagnostic accuracy in localization, improved surgical skills,
and better perioperative medical management [14, 15]. In
general, preoperative medical management is accomplished
by sequential 𝛼-blockade followed by 𝛽-blockade along
with restoration of adequate circulating volume to replenish
intravascular volume reduced from catecholamine-induced
vasoconstriction. The most widely used alpha antagonist for
PCCs is phenoxybenzamine, a nonselective alpha adrenergic blocker. In general dose is titrated to effect, up to
1 mg/kg/day [16]. Major side effects include reflex tachycardia
and sedation, and the long half-life of the drug can lead
to sustained hypotension after tumor resection. Selective
alpha-1 antagonists such as prazosin and doxazosin may be
associated with less reflex tachycardia; however, clinical studies comparing either to phenoxybenzamine have not been
conclusive. Beta blockers, typically metoprolol or propranolol, are effective at preventing or treating catecholamineinduced tachyarrhythmias; however, their use as front-line
agents is contraindicated until effective 𝛼-blockade has been
established due to unopposed 𝛼-adrenergic stimulation by
catecholamine excess [17].
PCCs and PGLs can occur sporadically or as part of an
inherited predisposition syndrome, most notably multiple
endocrine neoplasia (MEN) syndromes 2A and 2B, neurofibromatosis (NF) type 1, and von Hippel-Lindau (VHL)
disease [18–22]. More recently, genes that encode proteins in
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the mitochondrial complex II, particularly the succinyl dehydrogenase components SDHD, SDHB, and SDHC, have been
identified as causative for PCC-PGL syndromes [1, 23–27].
Roughly a third of PCCs occur in the setting of an inherited
cancer syndrome and the likelihood of a global predisposition
syndrome underlying a PCC or PGL is higher for children
than adults [28, 29]. Our patient was found to harbor a p.R27∗
point mutation in SDHB (c.79C>T) creating a premature stop
codon in exon 2 and establishing the diagnosis of SDHBrelated hereditary paraganglioma-pheochromocytoma syndrome [30]. SDHB mutations, known to predispose to PGLs
and PCCs, also increase risk of renal cell carcinoma [31].
Letouzé and coworkers recently reported that SDHx mutations lead to excess methylation and epigenetic silencing of
key genes involved in neuroendocrine differentiation, thereby
contributing to malignant degeneration of cells [32]. In one
series studying patients with SDHB mutations, the mean age
at diagnosis was 33.7 years with most patients presenting
with extra-adrenal tumors [30]. On reviewing the literature,
we found that PCC/PGLs associated with SDHB mutations
have been described in children as young as eight years
old; however, most pediatric SDHB-associated PCC/PGLs
present in adolescence [33–35]. SDHB mutations are known
to be highly penetrant, with lifetime risk of PGL/PCC as high
as 77–100% and lifetime risk of renal cell carcinoma estimated
to be 10–20% [35].
Overall, children with PCC have an excellent long-term
prognosis. In one large-scale study, mean life expectancy was
62 years among patients with hereditary PCC/PGL; however,
SDHB mutations are associated with more aggressive disease
in terms of early age at diagnosis, higher metastatic potential,
recurrence, and the development of other primary malignancies (PCC, PGL, and renal cell carcinomas) [36, 37]. As a
result, our patient will be monitored closely including every
three-month history and physical clinic visits accompanied
by plasma chromogranin A and metanephrine testing along
with abdominal ultrasonography. We plan yearly FDG-PET
or DOPA-PET scans [38]. Perhaps most importantly, we
have instructed the patient and her family to report signs
of catecholamine excess (diaphoresis, tachycardia, flushing,
headache, and hypertension) to us as rapidly as possible
should they develop between clinic visits. Thus far, the patient
is well, now almost nine months since her initial presentation,
without evidence of disease. Genetic evaluation of other
family members for SDHB mutations is in progress, along
with genetic counseling regarding the implications of the
patient’s identified cancer syndrome. It is critical to evaluate
patients for inherited cancer predisposition syndromes in
order to understand what tumor(s) and other conditions
the patient may be at risk for, to develop an appropriate
surveillance plan to monitor the patient for sequelae specific
to the particular genotype, to provide genetic counseling to
the patient, and to offer genetic testing and counseling to the
patient’s family [39, 40].
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